IL183284A - Methods to identify or assist in identifying individuals at risk of AMD - Google Patents
Methods to identify or assist in identifying individuals at risk of AMDInfo
- Publication number
- IL183284A IL183284A IL183284A IL18328407A IL183284A IL 183284 A IL183284 A IL 183284A IL 183284 A IL183284 A IL 183284A IL 18328407 A IL18328407 A IL 18328407A IL 183284 A IL183284 A IL 183284A
- Authority
- IL
- Israel
- Prior art keywords
- individual
- macular degeneration
- related macular
- age related
- risk
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract 20
- 208000002780 macular degeneration Diseases 0.000 claims abstract 20
- 101150030967 CFH gene Proteins 0.000 claims 12
- 108700028369 Alleles Proteins 0.000 claims 7
- 230000002596 correlated effect Effects 0.000 claims 4
- 238000003205 genotyping method Methods 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000054766 genetic haplotypes Human genes 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 abstract 2
- 108010053085 Complement Factor H Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62936304P | 2004-11-18 | 2004-11-18 | |
| US64947905P | 2005-02-02 | 2005-02-02 | |
| US67234605P | 2005-04-18 | 2005-04-18 | |
| PCT/US2005/041664 WO2006062716A2 (en) | 2004-11-18 | 2005-11-18 | Methods and compositions for treating ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL183284A0 IL183284A0 (en) | 2007-09-20 |
| IL183284A true IL183284A (en) | 2014-09-30 |
Family
ID=36578383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL183284A IL183284A (en) | 2004-11-18 | 2007-05-17 | Methods to identify or assist in identifying individuals at risk of AMD |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090017029A1 (https=) |
| EP (1) | EP1836312B1 (https=) |
| JP (2) | JP2008520242A (https=) |
| KR (1) | KR101290621B1 (https=) |
| CN (2) | CN102618644A (https=) |
| AT (1) | ATE528410T1 (https=) |
| AU (1) | AU2005314461B2 (https=) |
| BR (1) | BRPI0518289A2 (https=) |
| CA (1) | CA2588270A1 (https=) |
| CY (1) | CY1112579T1 (https=) |
| DK (1) | DK1836312T3 (https=) |
| ES (1) | ES2375490T3 (https=) |
| IL (1) | IL183284A (https=) |
| WO (1) | WO2006062716A2 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2505784A1 (en) | 2002-11-25 | 2004-06-10 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| ES2432112T3 (es) | 2004-02-10 | 2013-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados |
| EP2357254A1 (en) | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| CA2610340C (en) | 2005-05-26 | 2016-02-16 | Vernon Michael Holers | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| WO2007120975A2 (en) * | 2006-02-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants in complement regulatory genes predict age-related macular degeneration |
| CA2638916A1 (en) * | 2006-02-13 | 2007-08-23 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| WO2007149567A2 (en) | 2006-06-21 | 2007-12-27 | Musc Foundation For Research Development | Targeting complement factor h for treatment of diseases |
| JP5431151B2 (ja) * | 2006-07-13 | 2014-03-05 | ユニバーシティー オブ アイオワ リサーチ ファンデーション | 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 |
| AU2016204271B2 (en) * | 2006-07-13 | 2018-04-19 | University Of Iowa Research Foundation | Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration |
| AU2007277125B2 (en) * | 2006-07-26 | 2013-08-01 | Yale University | Diagnosis and treatment of age related macular degeneration |
| CN101173314B (zh) * | 2006-10-18 | 2010-12-01 | 四川省医学科学院（四川省人民医院） | 检测老年黄斑变性疾病的试剂盒 |
| CN106188303A (zh) | 2006-11-02 | 2016-12-07 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| GB0701213D0 (en) * | 2007-01-23 | 2007-02-28 | Univ Cardiff | Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| US7972787B2 (en) * | 2007-02-16 | 2011-07-05 | Massachusetts Eye And Ear Infirmary | Methods for detecting age-related macular degeneration |
| CA2680344A1 (en) | 2007-03-14 | 2008-11-20 | Woodruff Emlen | Humaneered anti-factor b antibody |
| JP5226256B2 (ja) * | 2007-07-26 | 2013-07-03 | ニプロ株式会社 | 加齢黄斑変性症の発症リスクの予測方法 |
| EP2217720A4 (en) * | 2007-11-01 | 2010-12-08 | Univ Iowa Res Found | RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII |
| US8114592B2 (en) | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| EP2278987A4 (en) * | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| CN103333952B (zh) * | 2008-11-05 | 2015-07-29 | 健泰科生物技术公司 | 年龄相关的黄斑变性中的遗传多态性 |
| US20120115925A1 (en) * | 2008-12-23 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Allelic Variants Associated with Advanced Age-Related Macular Degeneration |
| KR100937720B1 (ko) * | 2009-04-20 | 2010-01-20 | 전남대학교산학협력단 | ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법 |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| MX2012005151A (es) | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
| US20130011857A1 (en) | 2010-02-12 | 2013-01-10 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Complement factor h for oxidative stress disease conditions |
| WO2011143637A1 (en) | 2010-05-14 | 2011-11-17 | The Regents Of The University Of Colorado, A Body Corporate | Improved complement receptor 2 (cr2) targeting groups |
| WO2011153234A2 (en) * | 2010-06-01 | 2011-12-08 | University Of Kentucky Research Foundation | Methods of inhibiting alu rna and therapeutic uses thereof |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| JP2014502953A (ja) | 2010-08-16 | 2014-02-06 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 細胞透過性治療薬の鼻腔内送達 |
| FR2983212A1 (fr) | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
| CN102707068B (zh) * | 2012-05-31 | 2015-03-18 | 北京大学 | 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| HRP20181451T1 (hr) | 2013-03-14 | 2018-12-28 | Baxalta Incorporated | Čimbenik h, namijenjen presađivanju |
| JP6484215B2 (ja) | 2013-03-14 | 2019-03-13 | バクスアルタ インコーポレイテッド | 関節リウマチの治療のためのｈ因子 |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| AU2014306867B2 (en) | 2013-08-12 | 2017-10-26 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
| US20150093331A1 (en) * | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
| KR102131973B1 (ko) * | 2013-12-30 | 2020-07-08 | 주식회사 케이티 | 개인 건강관리 방법 및 시스템 |
| HUE050921T2 (hu) * | 2014-02-26 | 2021-01-28 | Allergan Inc | C5 komplementkomponens antitestek |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| EP3137503A1 (en) | 2014-05-01 | 2017-03-08 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
| KR102314785B1 (ko) * | 2015-04-21 | 2021-10-19 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| WO2017075252A1 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibody variant conjugates and uses thereof |
| CN106248969A (zh) * | 2015-11-01 | 2016-12-21 | 李倩 | 一种用于检测眼科疾病的试剂盒及其检测方法 |
| PT3384049T (pt) * | 2015-12-03 | 2023-08-18 | Regeneron Pharma | Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf |
| KR102011182B1 (ko) * | 2016-10-07 | 2019-08-16 | 단국대학교 천안캠퍼스 산학협력단 | 익상편 과발현 유전자 및 이의 용도 |
| JP2020516607A (ja) | 2017-04-07 | 2020-06-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| AU2018386304B2 (en) | 2017-12-15 | 2023-12-07 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| EP3824095A4 (en) * | 2018-07-20 | 2022-04-20 | University of Utah Research Foundation | GENE THERAPY FOR MACULATE GENERATION |
| WO2020180147A2 (ko) * | 2019-03-07 | 2020-09-10 | (주)레티마크 | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 |
| CA3167756A1 (en) * | 2020-02-04 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| CN113293206A (zh) * | 2021-07-23 | 2021-08-24 | 西安医臻生物医药科技有限公司 | 一种快速鉴别老年黄斑病变风险的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA2336703A1 (en) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| US20020032319A1 (en) * | 2000-03-07 | 2002-03-14 | Whitehead Institute For Biomedical Research | Human single nucleotide polymorphisms |
| AU2001261103B2 (en) * | 2000-04-29 | 2007-08-23 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| CN1466953A (zh) * | 2003-01-15 | 2004-01-14 | 哈佛东方生物医药（云南）有限公司 | 预防治疗老年黄斑变性的复合制剂 |
| EP2357254A1 (en) * | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
-
2005
- 2005-11-18 CN CN2012100868621A patent/CN102618644A/zh active Pending
- 2005-11-18 BR BRPI0518289-1A patent/BRPI0518289A2/pt not_active IP Right Cessation
- 2005-11-18 AU AU2005314461A patent/AU2005314461B2/en not_active Ceased
- 2005-11-18 AT AT05851755T patent/ATE528410T1/de active
- 2005-11-18 EP EP05851755A patent/EP1836312B1/en not_active Expired - Lifetime
- 2005-11-18 CN CN2005800467319A patent/CN101142321B/zh not_active Expired - Fee Related
- 2005-11-18 KR KR1020077013736A patent/KR101290621B1/ko not_active Expired - Fee Related
- 2005-11-18 DK DK05851755.8T patent/DK1836312T3/da active
- 2005-11-18 ES ES05851755T patent/ES2375490T3/es not_active Expired - Lifetime
- 2005-11-18 CA CA002588270A patent/CA2588270A1/en not_active Abandoned
- 2005-11-18 JP JP2007543226A patent/JP2008520242A/ja not_active Withdrawn
- 2005-11-18 US US11/791,025 patent/US20090017029A1/en not_active Abandoned
- 2005-11-18 WO PCT/US2005/041664 patent/WO2006062716A2/en not_active Ceased
-
2007
- 2007-05-17 IL IL183284A patent/IL183284A/en not_active IP Right Cessation
-
2011
- 2011-09-16 US US13/235,289 patent/US20120135000A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000185A patent/JP2012080900A/ja active Pending
- 2012-01-11 CY CY20121100030T patent/CY1112579T1/el unknown
-
2013
- 2013-09-26 US US14/038,602 patent/US20140018306A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008520242A (ja) | 2008-06-19 |
| CN101142321B (zh) | 2012-06-06 |
| CY1112579T1 (el) | 2016-02-10 |
| HK1113690A1 (en) | 2008-10-10 |
| EP1836312B1 (en) | 2011-10-12 |
| JP2012080900A (ja) | 2012-04-26 |
| ATE528410T1 (de) | 2011-10-15 |
| US20140018306A1 (en) | 2014-01-16 |
| AU2005314461B2 (en) | 2012-02-02 |
| WO2006062716A3 (en) | 2006-10-05 |
| US20120135000A1 (en) | 2012-05-31 |
| CN102618644A (zh) | 2012-08-01 |
| WO2006062716A2 (en) | 2006-06-15 |
| IL183284A0 (en) | 2007-09-20 |
| DK1836312T3 (da) | 2012-03-12 |
| BRPI0518289A2 (pt) | 2008-11-11 |
| EP1836312A2 (en) | 2007-09-26 |
| AU2005314461A1 (en) | 2006-06-15 |
| KR20070105969A (ko) | 2007-10-31 |
| CN101142321A (zh) | 2008-03-12 |
| CA2588270A1 (en) | 2006-06-15 |
| KR101290621B1 (ko) | 2013-07-29 |
| ES2375490T3 (es) | 2012-03-01 |
| US20090017029A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183284A (en) | Methods to identify or assist in identifying individuals at risk of AMD | |
| Pérez O’Brien et al. | Assessing signatures of selection through variation in linkage disequilibrium between taurine and indicine cattle | |
| Seco et al. | Allelic mutations of KITLG, encoding KIT ligand, cause asymmetric and unilateral hearing loss and Waardenburg syndrome type 2 | |
| WO2002097047A3 (en) | Compositions and methods for the inference of pigmentation traits | |
| FI20050011A7 (fi) | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi | |
| WO2005111233A3 (en) | Methods and kits to detect hereditary angioedema type iii | |
| WO2005082110A3 (en) | Haplotype markers for diagnosing susceptibility to immunological conditions | |
| Domingues et al. | A genetic linkage study in Brazil identifies a new locus for persistent developmental stuttering on chromosome 10 | |
| AU2003259222A1 (en) | Method of diagnosing alzheimer's disease | |
| CN105940115B (zh) | 恶性疟原虫青蒿素耐药性的分子标记物 | |
| Chu et al. | Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes | |
| WO2007086980A3 (en) | Methods of determining the risk of developing coronary artery disease | |
| FI20040255A0 (fi) | Menetelmä pre-eklampsian riskin havaitsemiseksi | |
| WO2010099468A3 (en) | Infertility associated defb-126 deletion polymorphism | |
| Roumeliotis et al. | Genomics in diabetic kidney disease: a 2024 update | |
| WO2003064600A3 (en) | The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes | |
| WO2007044780A3 (en) | Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies | |
| US20070254288A1 (en) | Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders | |
| WO2008035204A3 (en) | Prediction and prophylactic treatment of type 1 diabetes | |
| WO2003048384A3 (en) | Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms | |
| WO2005118854B1 (en) | Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies | |
| WO2003100090A3 (en) | Protein c polymorphisms | |
| WO2006097463A3 (en) | Compositions and methods for treating and diagnosing inflammatory disorders | |
| WO2006069592A3 (en) | Method for diagnosing an/or predicting preeclampsia and/or related disorders | |
| WO2004003229A3 (en) | Disease risk estimating method using sequence polymorphisms in a specific region of chromosome 19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |